Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | DVL1 | O14640 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5489263 | 0.91 | ALDH1A1 (0.56) | L3MBTL1ALDH1A1MAPTCYP1A2CYP2C9 | |
| SCHEMBL29463785 | 0.91 | ALDH1A1 (0.56) | L3MBTL1ALDH1A1MAPTCYP1A2CYP2C9 | |
| SCHEMBL1890195 | 0.85 | ALDH1A1 (0.52) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5472798 | 0.85 | FFAR1 (0.55) | L3MBTL1GLA | |
| SCHEMBL14431528 | 0.84 | MEN1 (0.47) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3782064 | 0.84 | LMNA (0.55) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1882466 | 0.83 | ALDH1A1 (0.44) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1883666 | 0.82 | ALDH1A1 (0.58) | L3MBTL1GLAALDH1A1MAPTCYP1A2 | |
| SCHEMBL1886694 | 0.81 | ALDH1A1 (0.46) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 | |
| Bromide SCHEMBL10998875 | 0.81 | ALDH1A1 (0.57) | L3MBTL1GLAALDH1A1MAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197626-A1 | Indoline derivatives | BAYER HEALTHCARE AG (DE) | 2007-08-23 | — | — | US | disclosed |
| US-20070197626-A1 | Indoline derivatives | BAYER HEALTHCARE AG (DE) | 2007-08-23 | — | — | US | disclosed |
| US-20070197626-A1 | Indoline derivatives | BAYER HEALTHCARE AG (DE) | 2007-08-23 | — | — | US | disclosed |
| EP-1675825-A2 | INDOLINE DERIVATIVES AS PPAR-DELTA MODULATORS | Bayer HealthCare AG (DE) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005019169-A2 | INDOLINE DERIVATIVES AS PPAR-DELTA MODULATORS | BAYER HEALTHCARE AG (DE) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197626-A1 | Indoline derivatives | PPARD, PPARA, PPARG | L3MBTL1 3469/4885GLA 1410/4885ALDH1A1 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.